• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Promethazine by Strides Shasun approved by USFDA

biospectrumasiaJuly 04, 2017

Tag: Promethazine , USFDA

Strides Shasun has recently received an approval from the United States Food & Drug Administration (USFDA) for Promethazine Hydrochloride Tablets USP, 12.5 mg, 25 mg, and 50 mg.

According to IMS data, the US market for Promethazine Hydrochloride Tablets USP, 12.5 mg, 25 mg, and 50 mg is approximately $ 17 million.

The product will be manufactured at the company’s flagship facility at Bangalore and marketed by Strides Pharma Inc. in the US Market.

Promethazine Hydrochloride Tablet is used to prevent and treat nausea and vomiting related to certain conditions and also to treat allergy symptoms such as rash, itching, and runny nose.

Previous:TissueGene awarded $750,000 Maryland Stem Cell Grant for Invossa clinical study

Next:Amgen’s uncontrolled LDL cholesterol lowering drug available in Singapore

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Promethazine by Strides Shasun approved by USFDA | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Promethazine Hydrochloride

Promethazine Hydrochloride
Promethazine Hydrochloride

Promethazine Hydrochloride
99% up GMP DMF Promethazine 60-87-7

99% up GMP DMF Promethazine 60-87-7
Eptifibatide acetate USFDA china manufacture 99%min

Eptifibatide acetate USFDA china manufacture 99%min
Promethazine   hydrochloride Tablets 

Promethazine   hydrochloride Tablets 
Promethazine Hydrochloride

Promethazine Hydrochloride
Promethazine EP Impurity C HCl

Promethazine EP Impurity C HCl
Promethazine hcl58-33-3

Promethazine hcl58-33-3
Dioxopromethazine Hydrochloride

Dioxopromethazine Hydrochloride
Promethazine Hcl+ Dextromethorphan Hydrobromide

Promethazine Hcl+ Dextromethorphan Hydrobromide

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service